Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDIO logo CDIO
Upturn stock ratingUpturn stock rating
CDIO logo

Cardio Diagnostics Holdings Inc (CDIO)

Upturn stock ratingUpturn stock rating
$3.79
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: CDIO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $60

1 Year Target Price $60

Analysts Price Target For last 52 week
$60 Target price
52w Low $3.22
Current$3.79
52w High $53.1

Analysis of Past Performance

Type Stock
Historic Profit 3.47%
Avg. Invested days 64
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.68M USD
Price to earnings Ratio -
1Y Target Price 60
Price to earnings Ratio -
1Y Target Price 60
Volume (30-day avg) 1
Beta 2.91
52 Weeks Range 3.22 - 53.10
Updated Date 08/29/2025
52 Weeks Range 3.22 - 53.10
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.75

Earnings Date

Report Date 2025-08-14
When -
Estimate -0.22
Actual -0.97

Profitability

Profit Margin -
Operating Margin (TTM) -22457.51%

Management Effectiveness

Return on Assets (TTM) -54.15%
Return on Equity (TTM) -97.67%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -737809
Price to Sales(TTM) 342.56
Enterprise Value -737809
Price to Sales(TTM) 342.56
Enterprise Value to Revenue 158.51
Enterprise Value to EBITDA -22.48
Shares Outstanding 1763130
Shares Floating 1630295
Shares Outstanding 1763130
Shares Floating 1630295
Percent Insiders 7.16
Percent Institutions 5.02

ai summary icon Upturn AI SWOT

Cardio Diagnostics Holdings Inc

stock logo

Company Overview

overview logo History and Background

Cardio Diagnostics Holdings Inc. is focused on cardiovascular disease detection through artificial intelligence (AI)-driven electrocardiogram (ECG) solutions. The company provides integrated genetic-clinical risk scores designed to improve the early detection and prevention of cardiovascular disease.

business area logo Core Business Areas

  • Integrated Genetic-Clinical Risk Scores: Offers integrated genetic-clinical risk scores for early detection and prevention of cardiovascular disease.
  • AI-Driven ECG Solutions: Develops and utilizes artificial intelligence to enhance the analysis and interpretation of electrocardiogram data.

leadership logo Leadership and Structure

Details on the specific leadership team and organizational structure of Cardio Diagnostics Holdings Inc. would require further research into the company's filings and website. Generally, such structures include a CEO, CFO, CTO, and board of directors.

Top Products and Market Share

overview logo Key Offerings

  • Epi+Gen CHD: A blood based genetic test providing a risk score for coronary heart disease. Market share is difficult to ascertain for this early stage company. Competitors include companies offering similar genetic tests or traditional cardiovascular risk assessment methods.
  • PrecisionCHD: Clinical test that uses patient's clinical data to identify and predict a patient's heart health. Market share is difficult to ascertain for this early stage company. Competitors include companies offering similar tests.

Market Dynamics

industry overview logo Industry Overview

The cardiovascular diagnostics industry is growing, driven by increasing prevalence of heart disease, advancements in diagnostic technologies, and a focus on preventative care.

Positioning

Cardio Diagnostics Holdings Inc. aims to differentiate itself through AI-driven solutions and integrated genetic-clinical risk scores, targeting early detection and personalized care.

Total Addressable Market (TAM)

The cardiovascular disease diagnostics market is estimated in the billions of dollars globally. Cardio Diagnostics Inc. aims to capture a share of this by focusing on more accurate and earlier disease detection.

Upturn SWOT Analysis

Strengths

  • AI-driven technology
  • Integrated genetic-clinical risk scores
  • Focus on early detection
  • Proprietary technology

Weaknesses

  • Limited market share as an early-stage company
  • Reliance on funding
  • Limited brand recognition
  • Regulatory hurdles for new diagnostic tests

Opportunities

  • Partnerships with healthcare providers
  • Expansion into new markets
  • Development of new diagnostic tools
  • Increasing awareness of preventative care

Threats

  • Competition from established diagnostic companies
  • Changing healthcare regulations
  • Technological advancements by competitors
  • Economic downturn affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • MYGN
  • ILMN
  • HOLX
  • NVTA

Competitive Landscape

Cardio Diagnostics Holdings Inc. competes with larger, more established diagnostic companies. Its advantage lies in its AI-driven approach, but it faces challenges in scaling and competing for market share.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data requires access to past financial reports.

Future Projections: Future growth projections are based on analyst estimates, which can vary. These are often tied to clinical trial results and commercialization success.

Recent Initiatives: Information on recent initiatives would be found in company press releases and investor presentations.

Summary

Cardio Diagnostics Holdings Inc. is an early-stage company with innovative AI-driven diagnostic technology targeting cardiovascular disease. While its technology holds promise, the company faces challenges in scaling, gaining market share, and securing funding. Success depends on partnerships, regulatory approvals, and demonstrating the clinical and economic value of its products. Investors should monitor clinical trial results and market adoption rates closely.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports (where available)
  • Industry Reports

Disclaimers:

This analysis is based on available information and is not financial advice. Market share data is estimated due to the limited public information available for Cardio Diagnostics Holdings Inc.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cardio Diagnostics Holdings Inc

Exchange NASDAQ
Headquaters Chicago, IL, United States
IPO Launch date 2022-01-14
Co-Founder, CEO & Director Dr. Meeshanthini V. Dogan Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 13
Full time employees 13

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.